| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2002 | EP1240179A2 3-methylene steroid derivatives for the treatment of autoimmune diseases |
| 09/18/2002 | EP1240177A2 Benzophenone alpha-d-glycopyranosides, preparation and therapeutic use |
| 09/18/2002 | EP1240176A1 Benzophenone glycopyranosides, preparation and therapeutic use |
| 09/18/2002 | EP1240172A1 New aminopropylphosphinic acids |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240166A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240165A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240164A1 Benzazole derivatives and their use as jnk modulators |
| 09/18/2002 | EP1240162A2 Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same |
| 09/18/2002 | EP1240161A1 Thienylalanine derivatives as inhibitors of cell adhesion |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240159A1 Improved omeprazole process and compositions thereof |
| 09/18/2002 | EP1240158A1 1-(aminophenyl)-2-pyrrolidones as integrin inhibitors |
| 09/18/2002 | EP1240157A2 Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect |
| 09/18/2002 | EP1240156A1 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1240155A1 Metal salts of 3-methyl-chromane or thiochromane derivatives |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240152A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 09/18/2002 | EP1240150A1 Macrocyclic compounds and their use |
| 09/18/2002 | EP1240148A1 Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii |
| 09/18/2002 | EP1240147A1 Potassium channel inhibitors |
| 09/18/2002 | EP1240146A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1240144A2 Compound having effect of promoting neuron differentiation |
| 09/18/2002 | EP1240143A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240142A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240141A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240137A1 Method for making 24(s)-hydroxyvitamin d 2 |
| 09/18/2002 | EP1240136A1 Use of biologically active vitamin d compounds for the prevention and treatment of inflammatory bowel disease |
| 09/18/2002 | EP1240133A1 Methods of preparing substituted tetracyclines with transition metal-based chemistries |
| 09/18/2002 | EP1240132A1 Adamantane derivatives |
| 09/18/2002 | EP1239923A2 Stabilized veterinary compositions comprising more than one antiviral agent |
| 09/18/2002 | EP1239884A2 Methods for preparing pharmaceutical formulations |
| 09/18/2002 | EP1239883A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239882A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239881A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239880A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239879A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239878A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239869A2 Tweak receptor |
| 09/18/2002 | EP1239868A2 Use of an immunosuppressant for increasing an antifungal activity of a lipopetide |
| 09/18/2002 | EP1239864A1 Treatment of heart rhythm disturbances with n6 -substituted-5'-(n-substituted) carboxamidoadenosines |
| 09/18/2002 | EP1239863A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 09/18/2002 | EP1239862A2 Pharmaceutical preparation for treating tumor diseases |
| 09/18/2002 | EP1239861A2 Combination of cyamemazine and an atypical neuroleptic |
| 09/18/2002 | EP1239860A1 Use of dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-despressants |
| 09/18/2002 | EP1239859A2 Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients |
| 09/18/2002 | EP1239858A2 The treatment of convulsive states |
| 09/18/2002 | EP1239857A1 Dual-release compositions of a cyclooxygenase-2- inhibitor |
| 09/18/2002 | EP1239856A1 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 09/18/2002 | EP1239855A2 Method for the prevention and/or treatment of atherosclerosis |
| 09/18/2002 | EP1239854A1 Use of a hypoglycemic agent for treating impaired glucose metabolism |
| 09/18/2002 | EP1239853A1 Fungicidal agent containing n-chlorotaurine and use thereof |
| 09/18/2002 | EP1239852A2 Bissulfonamide derivatives as enzyme inhibitors |
| 09/18/2002 | EP1239851A1 Treatment of hyperproliferative disorders |
| 09/18/2002 | EP1239850A1 Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-n-methyl-ethylammonium chloride as anti-inflammatory agents |
| 09/18/2002 | EP1239849A2 Pharmaceutical formulations comprising resveratrol and use thereof |
| 09/18/2002 | EP1239848A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 09/18/2002 | EP1239847A1 Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy |
| 09/18/2002 | EP1239846A2 Transdermal administration of phenylpropanolamine |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239844A1 Process for producing nanometer particles by fluid bed spray-drying |
| 09/18/2002 | EP1239843A1 New (aminopropyl)methylphosphinic acids |
| 09/18/2002 | EP1239841A1 Pharmaceutical formulations comprising sodium amoxycilline and potassium clavulanate |
| 09/18/2002 | EP1239840A2 Antiviral medication |
| 09/18/2002 | EP1239839A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 09/18/2002 | EP1239837A2 Direct compression polymer tablet core |
| 09/18/2002 | EP1239832A2 Suspension comprising oxcarbazepine |
| 09/18/2002 | EP1239831A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 09/18/2002 | EP1239829A1 Devices for the delivery of drugs having antiprogestinic properties |
| 09/18/2002 | EP1239828A1 Use of cationic compounds |
| 09/18/2002 | EP1239826A2 Cosmetic and/or pharmaceutical preparations |
| 09/18/2002 | EP1239825A1 Catechol oximes and their use in cosmetic and dermatological preparations |
| 09/18/2002 | EP1239824A2 Scar treatment composition comprising a silicone mixture |
| 09/18/2002 | EP1239814A2 Use of the residues from wine production |
| 09/18/2002 | EP1239791A1 Dental prosthesis with means for the release of active substances |
| 09/18/2002 | EP1239776A2 Surgical needle with weeping tip and method of use |
| 09/18/2002 | EP1212339A4 2'-o-acetamido modified monomers and oligomers |
| 09/18/2002 | EP1117633B1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 09/18/2002 | EP1104762B1 Substituted imidazo[1,2a]azines as selective inhibitors of cox-2 |
| 09/18/2002 | EP1095029B1 Piperazine derivatives inhibiting human immunodeficiency virus replication |
| 09/18/2002 | EP1056461B1 Glucocorticoids for treating glomerulonephritis |
| 09/18/2002 | EP1039884B1 A method for the prevention and treatment of stunned myocardium |
| 09/18/2002 | EP1036059B1 Adamantane derivatives |
| 09/18/2002 | EP1000034B1 Substituted 6-alkylphenanthridines |
| 09/18/2002 | EP0994854B1 Method for preparing a substituted perhydroisoindole |
| 09/18/2002 | EP0981748A4 Signal enhancement of bispecific antibody-polymer probe for immunoassay use |
| 09/18/2002 | EP0975573B1 Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
| 09/18/2002 | EP0954565A4 Adipogenic differentiation of human mesenchymal stem cells |
| 09/18/2002 | EP0952837B1 Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesteremic agents |
| 09/18/2002 | EP0950056B1 N-(pyridinylamino)isoindolines and related compounds |
| 09/18/2002 | EP0944386B1 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| 09/18/2002 | EP0944321B1 Compositions for the systemic control of parasites of warm-blooded animals |
| 09/18/2002 | EP0934259B1 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 09/18/2002 | EP0929516B1 Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect |
| 09/18/2002 | EP0918742B1 Water-miscible esters of monoglycerides having antimicrobial activity |
| 09/18/2002 | EP0917528B1 New amidino derivatives and their use as thrombin inhibitors |
| 09/18/2002 | EP0915697B1 Anticonvulsant sulfamate derivatives useful in treating obesity |